Nicotinamide is a water-soluble vitamin B3 derivative that has many roles in medicine. This review examines the role of nicotinamide in dermatology and its actions in preventing photoageing and skin cancers in humans. Nicotinamide prevents ultraviolet radiation (UV) from reducing ATP levels and inhibiting glycolysis, thus preventing the UV radiation-induced energy crisis. This enhances DNA repair and reduces UVinduced suppression of immunity. Randomised controlled clinical trials have also shown that nicotinamide reduces transepidermal water loss and the development of new non-melanoma skin cancers in high-risk humans. This review also examines nicotinamide's safety profile.
| NICOTINAMIDE IN DERMATOLOGY
Nicotinamide (NAM) is a water-soluble compound, found in foods such as meat, fish, legumes, mushrooms, nuts and grains. [1] It is metabolised by the liver and is excreted by the kidneys. [2] NAM is also a by-product of tryptophan metabolism, with approximately 50% produced by this metabolic synthesis. [3] Nicotinamide is a key component of the glycolysis pathway, generating NAD+ for ATP production, to maintain cellular energetics and influence a variety of metabolic processes. [4] Nicotinamide deficiency, or pellagra, particularly affects organs with high cellular energy requirements and is thus characterised by (photosensitive) dermatitis, diarrhoea and dementia. [3] Nicotinamide has anti-inflammatory effects which can ease the symptoms of pruritus [4] and has been reported to be effective in the treatment of rosacea, acne [5] and autoimmune blistering disorders such as bullous pemphigoid. [6] Oral NAM reduces transepidermal water loss (TEWL) by ~6%-7% as early as 3 months after commencement of doses of 1 g daily, [7] and topical 2% NAM applied twice daily over 4-8 weeks provides a more effective moisturiser as measured by a reduction in TEWL, when compared with white petroleum alone (P < 0.05). [8] Hence, NAM seems to enhance skin barrier function, which may contribute to its efficacy in rosacea and acne, and may make it an adjunctive treatment for dermatitis, [4, 9] as these skin conditions demonstrate increased transepidermal water loss within the stratum corneum, when compared to healthy skin. [10] [11] [12] Nicotinamide has also been used topically for pigmentary disorders; NAM suppresses the transfer of melanosomes from melanocytes to keratinocytes and decreases the cutaneous pigmentation characteristic of melasma. [13, 14] 
| Nicotinamide and photoprotection
Early studies by Gensler et al in 1997 and 1999 found that topical and oral NAM prevented UV-induced immune suppression and tumor formation in mice. [15, 16] Several years later, a number of studies from our group were able to translate Gensler's early murine findings to humans. NAM in both topical and oral forms has similar effects in reducing UV immune suppression [17] [18] [19] and the development of non-melanoma skin cancers [20] in humans.
Exposure to UV radiation (UVA and UVB wavebands) causes photoageing of the skin and the development of skin cancers via a range of mechanisms including direct cell damage (via substitutions in DNA of pyrimidines, gene mutations and oxidative stress), the activation of local inflammatory responses, suppression of cutaneous anti tumor immunity [19] and the creation of an "energy crisis" in skin cells which hinders effective DNA repair [1, 21] , see Figure 1 .
| U V AND CELLUL AR DNA DAMAG E
Direct damage to DNA in human keratinocytes by UV results in the formation of cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidine photoproducts (6-4PPs). [22] UVA additionally causes singlet oxygen-induced DNA photolesions including 8-oxo-7,8-dihyd ro-2′deoxyguanosine (8oxoG). [22] These UV-induced CPDs give rise to C→T and CC→TT transitional mutations within DNA, increased levels of which are found in animal and human models of BCC and SCC. These UV-induced mutations can alter the function of the p53 gene, [23] an important tumor suppressor gene in skin carcinogenesis. [19] Mutations of p53 are an important step in the dysregulation of epidermal cell growth in the pathway leading to malignancy. Both animal and human skin models have found increased C→ T and CC→TT transitional mutations in the p53 gene in SCCs, BCCs and melanoma. [19, 23] 
| NI COTINAMIDE ENHAN CE S REPAIR OF U V-INDUCED DNA DAMAG E
Surjana et al's [24] 2013 study of solar-simulated UV-irradiated NAMtreated human HaCaT keratinocytes demonstrated an increased amount and rate of DNA excision repair in cells treated with nicotinamide. Keratinocytes were treated with NAM or vehicle and exposed to UV irradiation. Initial post-UV exposure levels of CPD and 8oxoG
photolesions amongst the two comparators were similar, indicating that nicotinamide did not reduce or prevent DNA damage. However, after 45 minutes, there were reduced CPD and 8oxoG photolesions in those keratinocytes treated with NAM. Assays measuring unscheduled DNA synthesis in the same model confirmed increased rates of DNA repair with NAM. [25] It therefore appears that by augmenting access to ATP in UV-irradiated keratinocytes, DNA repair is increased, which would reduce both UV-induced immune suppression and the formation of mutations in oncogenes and tumor suppressor genes.
| NICOTINAMIDE REDUCE S U V-INDUCED INFL AMMATION
Ultraviolet B irradiation of the skin leads to the production of proinflammatory cytokines which induce inflammation and cell death.
The cytokines produced by UVB-irradiated keratinocytes include IL-1, IL-6, IL-8, IFN-γ, granulocyte colony-stimulating factor (C-GSF), macrophage inflammatory protein (MIP-β) and TNF-α. [26] In 2013, Monfrecola et al [27] studied the effects of NAM on UVinduced inflammatory cytokine production in human keratinocytes, ex vivo. HaCaT cells (immortalised human keratinocyte cell line) were treated with NAM and then subjected to UV irradiation. Those that had been pre treated with NAM showed significant downregulation of IL-6, IL-10, MCP-1 and TNF-α mRNA expression, indicating F I G U R E 1 Nicotinamide and Photoprotection. UVA and UVB within sunlight causes damage in the skin including CPD, 6-4PP and 8oxoG damage to DNA, suppression of cellular immunity and activation of inflammatory responses. Nicotinamide, a precursor to NAD increases ATP production which increases DNA repair, protecting from photodamage. See text for definitions of abbreviations effectiveness in suppressing local inflammatory responses. In vivo in humans, however, NAM did not reduce the erythema caused by UV radiation, with two studies showing no significant change in minimal erythema dose in humans receiving nicotinamide orally at 500 mg or 1500 mg daily [19] , nor when NAM was applied topically either before or immediately after low-dose UV exposure.
[17]
| Nicotinamide reduces UV radiation-induced cellular energy depletion
The repair and regeneration of damaged skin cells require energy, in the form of ATP. Studies of in vivo murine epidermis and cultured human keratinocytes indicate that UVB depletes NAD+ [25] , an essential coenzyme required in the production of ATP [25] , making these skin cells more sensitive to DNA damage, and placing them at risk of tumorigenesis through the reduction in DNA repair mechanisms.
It is possible that the depletion of ATP and NAD in UV-damaged skin cells is via UV's activation of poly-ADP-ribose polymerase 1
(PARP-1), an enzyme that has central functions in DNA repair and genomic stability. [25] PARP-1 blocks NAD+ generation by the glycolytic pathway, reducing intracellular energy supplies. [1] Nicotinamide prevents this reduction in energy supply by in turn, inhibiting the PARP-1 blockade of the glycolytic pathway-driven production of NAD and ATP. Additionally, NAM, as a precursor to NAD, is able to increase intracellular ATP levels independently to this inhibition of PARP-1.
[1] PARP-1 also enhances the expression of various proinflammatory mediators in murine models, [28] and hence, NAM may also exert anti-inflammatory effects via the PARP pathway.
These findings of NAM's ability to repair UV-induced photolesions were reproduced in Thompson et al.'s paper investigating DNA repair in primary melanocytes, indicating its potential in protecting against DNA damage leading to melanoma, [22] an area for further study.
| NI COTINAMIDE PROTEC TS FROM U V-INDUCED IMMUNE SUPPRE SS ION
Ultraviolet irradiation diminishes local cutaneous immune responses even at very low, suberythermal doses, [23] for example, levels equivalent to <8 minutes of midday summer sunlight. [29] UV reduces immune responses of the skin by a number of mechanisms, including reducing tumor antigen-presenting cell function [21, 25] and increasing the production of immunomodulatory cytokines [25] which results in diminished UV-induced contact and delayed-type hypersensitivity responses. [21] Unrepaired DNA photolesions in the skin are a key trigger for UV-induced immune suppression. [30] To investigate NAM's ability to modulate UV's local immunesuppressive effects, Yiasemides et al [19] used the Mantoux reaction in which tuberculin protein is injected intradermally to elicit a delayedtype hypersensitivity (DTH) response in healthy tuberculin-positive volunteers. Two groups of healthy volunteers in this double-blinded crossover trial were randomised to receive 500 mg oral NAM or placebo once daily (n = 16) or three times daily (n = 15), respectively, for 7 days and then after a 4-week washout period received the alternate intervention for 7 days. During each intervention, volunteers also received low doses of solar-simulated UV irradiation on their lower backs daily for 3 days, followed by Mantoux testing at irradiated and adjacent unirradiated sites. Mantoux reactions at each site were then quantitated using a reflectance erythema metre in order to determine the magnitude of UV immune suppression with each intervention. Nicotinamide significantly lowered UV immune suppression compared to placebo, providing similar levels of immune protection at 500 and 1500 mg daily. Topical nicotinamide has also been shown to be immune protective against both narrowband UVB (310 nm) and narrowband long wave UVA (370 nm). [18] These findings illustrate NAM's ability to significantly reduce the immunesuppressive effects of UV radiation in humans, confirming Gensler's earlier studies of both topical and oral nicotinamide in mice. [16] Importantly, nicotinamide did not alter immune responses at unirradiated sites [19] indicating that it acts to normalise cutaneous immune responses rather than boosting baseline immunity.
| Nicotinamide reduces actinic keratoses (AK) and skin cancer in high-risk individuals
In 2012, Surjana et al [24] reported on nicotinamide's ability to reduce AK counts in otherwise healthy volunteers. A total of 72 individuals with a minimum of four palpable AKs (head, neck or upper arms)
were recruited over two phases to receive either placebo or nicotinamide (500 mg BD). After 4 months, they reported a relative reduction rate of 29%-35% in AK counts. Additionally, of these patients, 11 patients receiving placebo developed 20 new NMSCs vs only four newly developed NMSCs in two patients taking nicotinamide, suggesting nicotinamide's promise for skin cancer chemoprotection.
In 2015, Chen et al [20] published the first Phase three study of oral NAM's ability to reduce skin cancer incidence in immune-competent individuals at high risk of skin cancer. A total of 386 adults (average age 66 ± 12 years; 63% men) were randomised to receive 500 mg nicotinamide twice daily vs placebo. "High risk" was defined as having had at least two non-melanoma skin cancers (NMSCs) in the previous 5 years. After 12 months of oral NAM, the incidence of new NMSC was reduced by 23% (P = 0.02), vs placebo. Nicotinamide's ability to reduce the number of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) was also shown to be similar, with relative rate reductions of 20% (P = 0.12) and 30% (P = 0.05), respectively. Additionally, the number of precancerous AK was 14% lower in the NAM group (P = 0.001). [20, 24] Despite BCCs and SCCs having different development pathways with different sun exposure patterns, [31] both forms of skin cancer require the development of DNA mutations. [23, 26] Both types of cancers are also seen in increased number in patients with suppressed immune systems, indicating that reduced skin immunity contributes to the development of both NMSCs. It is hypothesised that NAM's ability to reduce the incidence of both BCC and SCC is thereby a result of its ability to enhance DNA repair, and boost skin immunity, [32] despite their different behaviour. It is unknown whether NAM's influence initiates repair of lesions that are already present or whether it promotes repair of newly formed lesions.
The effect of NAM in reducing NMSCs was not maintained at 6-month follow-up, indicating no long-term efficacy after ceasing nicotinamide, and that NAM needs to be administered continuously to maintain its photoprotective effects. A similar trend is also observed with retinoid therapy; in that continuous administration is required for continued chemopreventive efficacy. [33, 34] 
| Nicotinamide and photoprotection in the immunosuppressed
Anti tumor immunity is a central defense against skin carcinogenesis. In chronically immune-suppressed solid organ transplant recipients, skin cancer incidence is much greater than that of the immune-competent population. [35] Skin cancers are also more aggressive in this population.
Additionally, the development of AKs is 250 times the rate in immunecompetent individuals, with rates of conversion to SCCs as high as 12%
in the immune suppressed with AKs totalling 50 or more. [36] Following on from our large randomised controlled trial of NAM for skin cancer chemoprevention in high-risk immune-competent patients, Chen et al [37] conducted a Phase 2 study with a similar placebo-controlled study design to investigate the effect of 500 mg twice daily oral NAM for 6 months in a small group (n = 22) of immunosuppressed renal transplant recipients. Despite the sample size being too small for results to reach significance, the data suggested that this population may also benefit from NAM. There was a (nonsignificant) reduction rate of NMSCs by 35% in the treatment group (P = 0.36) and a (non-significant) 16% reduction in AKs (P = 0.15), results consistent with those observed in Chen et al's [20] larger ONTRAC trial. Additionally, NAM was well tolerated with no safety concerns identified in this small cohort of transplant recipients. [37] Drago et al [38] investigated the effect of NAM 500 mg daily on AKs in solid organ transplant recipients at the University of Genoa.
Thirty-eight patients were recruited (eight liver and 30 kidney transplants), with 19 assigned to NAM 500 mg/d vs controls. They reported a reduction in size of AKs in 88% of patients receiving NAM. Fourty two percent of those receiving NAM showed complete regression of AKs, and no patient assigned to NAM developed any new AKs. In contrast, 91% of the control group showed an increase in AKs and/or new AKs. Additionally, within the control group, seven AKs progressed to SCC, [38] whereas no skin cancers were reported in the NAM group.
| SAFE T Y PROFILE

| Nicotinic Acid vs Nicotinamide
Nicotinic acid (niacin), an alternative form of vitamin B3, has for decades been used to treat elevated cholesterol and reduce the cardiovascular events and progression rate of atherosclerotic disease. [39] Known side effects of nicotinic acid include flushing, nausea and vomiting, hypotension, headaches and itch, [40] presumably due to its vasodilatory effects [41] and release of prostaglandin D2 and other eicosanoids from the skin. [42] These vasodilatory side effects are not generally observed with NAM. [43] In an attempt to combat this side effect profile of immediate release nicotinic acid, an extended release compound (ERN) was created in combination with laropiprant (LRPT), a prostaglandin inhibitor (ERN-LPRT). Two large studies, the AIM-HIGH and HPS2-THRIVE, used this ERN and ERN-LPRT product vs a statin-placebo product to investigate nicotinic acid's role in reducing cholesterol and minimising progression to cardiovascular events in patients with established cardiovascular disease. Despite resulting in significant improvements in HDL cholesterol and triglyceride levels, neither study proved any additional reduction in cardiovascular risk with the addition of niacin to statin. [44, 45] A pooled analysis of these studies also found that the addition of a prostaglandin did not improve the side effect profile of nicotinic acid.
[46]
| Side effects of Nicotinic Acid
The pooled safety analysis results of over 11 000 patients who participated in the AIM-HIGH and HPS2-THRIVE studies found the following adverse events deemed by investigators as treatmentrelated, serious or led to discontinuation of either ERN-LPNRT or ERN-NSP [46] : nausea and vomiting (11.7%-15.3%), diarrhoea (3.4%-4.2%), headache (3.2%-3.6%), paraesthesia (3.5%-4.4%), erythema (1.7%-2.9%), pruritus (8.2%-8.3%), rash (2.8%-3.1%) and flushing (13.6%-23.3%). The most common laboratory adverse events related to nicotinic acid in these studies were increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine kinase (CK), blood glucose and blood uric acid. [46] Additional side effects of nicotinic acid have also been reported as exacerbation of peptic ulcers, increased insulin resistance and hyperglycaemia, cystoid macular oedema (rare), and small reductions in platelet counts and increased prothrombin time.
[47]
| Side effects of Nicotinamide
In comparison, studies of NAM report far greater tolerability, with few side effects reported at doses of up to 3 g daily in diabetic populations. [43] It is presumed that the absence of a carboxyl group on the pyridine nucleus of NAM, compared to nicotinic acid, may be responsible for the differences in side effect profiles of these two agents.
[48]
| High-dose Nicotinamide
Since Greenbaum et al's [49] first report on the use of NAM in childhood schizophrenia in 1970, the role of high-dose NAM has been reviewed in a number of papers, with varied discussion on its side effects. Knip et al's [43] 2000 literature review describes a favourable safety profile of NAM, based on 19 studies prior to 2000 (mainly of diabetic population groups). Since then, a further nine studies have reported on NAM's use in a range of groups, including the general population, [20] in patients at high risk for diabetes, [48] and in patients with end-stage renal disease (ESRD) requiring haemodialysis, both adult [50] [51] [52] [53] [54] and paediatric [55] [ Table 1 ].
| The ONTRAC study
Chen et al's 2015 Phase 3 trial of NAM's effect (1 g daily) in reducing
NMSCs in a high-risk, largely elderly population found no clinically significant difference between the rate of occurrence of adverse events between NAM and placebo groups. There was no significant difference between the study groups with respect to changes in weight, blood pressure, haemoglobin, white cell count, platelet count, or levels of creatinine, alkaline phosphatase, y-glutamyl transferase, alanine aminotransferase or aspartate aminotransferase measured at baseline and at 12 months.
[20]
| European Nicotinamide Diabetes Intervention Trial (ENDIT)
Gale et al's [48] publication of the ENDIT study reported 35 adverse events. These showed no significant difference in occurrence rate between the NAM and placebo groups (18 patients NAM vs 15 placebo). In this randomised controlled trial, NAM at doses between 500 and 3000 mg/d was administered for 5 years. In the study by
Gale et al, [48] it was reported that between the two groups, the number of adverse events, the body system affected or the severity of each event did not show predilection for the treatment group. Nine of the 522 patients had elevated liver transaminases, five from the NAM group and four from the placebo group.
| Paediatric population
Similarly, Elliott et al's [56] was no other mention of adverse effects, and their overall conclusion was that NAM is safe in humans at the dose delivered.
| NAM in patients with end-stage renal disease
A number of recent studies have investigated NAM's action in reducing phosphate levels in patients with end-stage renal disease (ESRD) requiring dialysis. [50, 51, [53] [54] [55] . Across these studies, the adverse events reported included reversible diarrhoea, thrombopenia and rash.
Nicotinamide inhibits sodium-dependant phosphate cotransporters in the renal proximal tubule and intestine. [54] This discovery has led to many studies of NAM in patients with chronic kidney disease and ESRD requiring haemolysis. These patients are at risk of hyperphosphataemia predisposing to secondary hyperparathyroidism, vascular disease and increased vascular calcification. [57, 58] In these patients, NAM at doses of _500 to 1500 mg/d significantly reduces phosphate levels by between 0.79 and 1.5 mg/ dL [50, 54] , with or without the presence of other readily available phosphate binders.
| Gastrointestinal disturbance
In the adult studies, diarrhoea was reported to occur in patients with ESRD requiring haemodialysis, with an average dose of NAM of 1000 mg/d or more, [51, 53, 54, 59] and at an incidence between 3% [54] and 23%. [51] . Chen et al [20] reported nine cases of (mild) diarrhoea in the NAM group (vs four in the placebo group), in otherwise healthy individuals. In a paediatric population of patients with ESRD requiring dialysis, this rate was reported higher at 33.3%. [55] The paediatric population experienced additional gastrointestinal symptoms of nausea and vomiting at rates of 30% and 7%, respectively. All reports of diarrhoea with NAM ceased promptly with either spontaneous resolution, [51] a dose reduction, [53, 54] or after ceasing the vitamin at the end of the study. [55] Following its metabolism into one of three possible by-products (methylation, oxidation or hydroxylation), NAM is excreted by the kidneys. [43] This dependence on renal excretion to clear concentrations of NAM's metabolic by-products may highlight a possible reason as to why NAM appears to be less tolerated in patients with renal failure.
Also in ESRD patients, Takahashi et al [50] reported that their 5 cases of diarrhoea (7.7%) occurred at dose of NAM >1500 mg/d.
Shahbazian et al's [53] study reported four patients (16.7%) with diarrhoea that occurred when their dose of NAM increased from 500 to 1000 mg/d. Their symptoms resolved with the reduction in NAM, as did Cheng et al's [54] one patient with diarrhoea, suggesting a possible dose-dependent relationship.
There has been some suggestion that the co-administration of other phosphate binders may contribute to the higher levels of diarrhoea reported in this patient population on haemodialysis, when compared to the general population. [54, 59] 
| Thrombopenia
Nicotinic acid can cause small reductions in platelet counts and increase prothrombin time. [47] Thrombopenia from NAM was reported in three adult studies and one paediatric study. It was reported as having occurred in varying degrees and only in patients with ESRD on dialysis. [50, 53, 54, 60] Takahashi et al [50] reported one case of thrombopenia (1.5%) in their study at a dose of NAM >1500 mg/d. It resolved 2 weeks after discontinuing nicotinamide, and there was no associated change in erythrocyte or leucocyte count. [50] Cheng et al [54] reported thrombopenia having occurred as an adverse event in both treatment and placebo groups. Nine patients in the NAM treatment group were categorised with thrombopenia with platelet counts <150 000/mm 3 vs five in the placebo group.
One patient taking NAM experienced thrombopenia with platelet count <100 000/mm 3 vs two patients in the placebo group.
Shahbazian et al [53] investigated platelet counts in dialysed patients after 4 weeks of 500 mg/d NAM and then at 8 weeks, after 
Reported Adverse Events
Studies of nicotinamide in the general population Gale et al [48] (ENDIT) NAM in preventing onset or delay of autoimmune diabetes 522 patients at high risk of DM1
1.5-3 g/d
Randomised controlled trial
Well tolerated in the general population
Chen et al [20] NAM in reducing NMSCs 386 high-risk skin cancer patients
Nil reported
Elliott RB et al [56] NAM for prevention of diabetes Study of nicotinamide in transplant patients (renal function eGFR >20) Chen et al [7] NAM to reduce NMSCs in transplant patients Cheng et al [54] NAM for phosphate reduction *with P04 binders 33 haemodialysis patients 500-1500 mg/d
Randomised, double-blind, placebo-controlled, crossover study 20 wk Diarrhoea × 1 (3%) Thrombopenia × 9
Rash × 1 this dose had been increased to 1000 mg/d. At week 4, there was no significant change to platelet count (P = 0.065) from baseline counts.
Two patients did show a reduction in platelet counts, but these were within normal limits and were deemed not significant when compared to placebo group. At week 8, following 4 weeks of an increased NAM of 1000 mg, six patients (25%) experienced thrombopenia of <100 000/mm 3 and two patients with thrombopenia of <150 000/ mm 3 . No patients in the placebo group experienced thrombopenia.
El Borolossy et al's [55] study of paediatric patients receiving haemodialysis also mentioned a tendency of patients on NAM to experience a drop in their platelet counts (P = 0.014), but as in Shahbazian's study, this reduction was maintained within the normal limits set for platelet counts.
Reassuringly, all 18 cases of thrombopenia across these three adult studies (122 patients in total taking NAM) were reported to have resolved on ceasing NAM. [50, 53, 54] Apart from one case of a prolonged haemostasis at the dialysis needle site after 8 weeks of highdose NAM, [51] no episodes were associated with clinically significant bleeding events or tendencies. [53] [54] [55] There appears to be a dose-dependent association between NAM and severity of thrombopenia in patients with renal impairment. [53] There has been no report of thrombopenia in patients without ESRD. [20, 37, 43, 48, 56] High-dose NAM (at 1 g/d) in solid organ transplant recipients is well tolerated, [37] and the two published reports of NAM in this immunosuppressed population group [20, 38] show no alteration in blood levels of immunosuppressants.
| Hepatotoxicity
Elevated liver enzymes are associated with extended release nicotinic acid, [47] and hepatotoxicity has been documented in a case study of NAM administration of >9 g/d [43] and in other reports of doses greater than 3 g daily. [43, 48] Of those studies which commented on blood sugar indices, none indicated changes induced by NAM, as opposed to the increased insulin resistance and hyperglycaemia which can occur with nicotinic acid.
| Flushing
In comparison with a reported incidence of flushing of 25%-40% with immediate release nicotinic acid, [47] this is not seen with NAM given either as an intravenous injection or orally at high doses. [20,37,48,50,51,53,55,56 ,60] The only reports of flushing occurred in El Borolossy's paediatric population requiring haemodialysis. [55] This was reported by eight patients (26.7%) after an average duration of 8 weeks of therapy, with all cases resolving spontaneously and with no need to stop NAM treatment.
| Nicotinamide In Pregnancy and Breastfeeding
Nicotinamide crosses the placenta, and there have been no teratogenic effects observed in murine studies. [43] It has, however, not been formally assessed in pregnancy in humans. The few patients who ceased taking NAM after falling pregnant in studies showed no congenital abnormalities on follow-up. [48] 
| CON CLUS IONS
Nicotinamide has a range of photoprotective and anti-inflammatory effects, and there is now Phase 3 level evidence of NAM's ability to reduce non-melanoma skin cancer and AKs in high-risk individuals.
Even at pharmacological doses of ~1 g daily, NAM is well tolerated, as highlighted by the reports of minimal, if any, side effects in large studies of patients with normal renal function. [20, 48] Increased reporting of diarrhoea was found in studies of patients receiving haemodialysis, with some mention of increased severity in those taking other phosphate binders. Thrombocytopaenia is an acute and isolated side effect that seems to be limited to patients with ESRD on haemodialysis. [53] Hepatotoxicity is rare but can occur at extremely high doses of NAM, greater than 3 g/d. In patients with ESRD requiring haemodialysis, blood levels should be monitored for the evaluation of thrombocytopaenia which is a possible side effect, but one that is reversed with cessation of NAM.
The future of NAM as a photoprotective agent is promising, with this paper highlighting its positive safety profile and showing evidence supporting its utility in those patients at high risk for the development of non-melanoma skin cancer.
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